Hepatitis B and C: Management and Treatment

ISBN-13: 9781841843698 / Angielski / Twarda / 2004 / 176 str.

Raymond Bonnett; Thierry Poynard

Opis

Chronic hepatitis B and C affect 520 million people worldwide, and are a major cause of chronic liver disease and of mortality, despite the efficacy of the vaccine. Hepatitis B and C: Management and Treatment provides a practical explanation of the natural history and management of the disease, and examines the benefits of the most recent drugs, and their effect, whether used in isolation or as part of a combination therapy. This second edition expands the coverage of treatment of various difficult-to-treat patients and will be a welcome guide to the physician in both clinical decision-making and in explaining the benefits and side effects to the patient.

Spis treści

Section 1: Hepatitis C. Introduction. Natural History of Hepatitis C: Epidemiology. Natural History of Hepatitis C: Hepatic Manifestations. Natural History of Hepatitis C: Extra-hepatic Manifestations and Quality of Life. Management Protocols in Chronic Hepatitis C. Management of Relapsers and Non Responders, Maintenance Therapy. Management of Patients with Cirrhosis. Management of Patients Co-infected by HCV and HIV. Management of HCV Infection Post Liver Transplantation. Management of Patients with Renal Disease. Safety of Interferon, Pegylated Interferon and Ribavirin. Who Need to be Treated? Cost-effectiveness of Treatment. Management of Acute Hepatitis C. Difficult-to-treat Patients. Practical Guidelines for the Management of Hepatitis C. New Drugs in Development. Section 2: Hepatitis B. Introduction. Natural History of Hepatitis B: Epidemiology. Natural History of Hepatitis B: Hepatic Manifestations. Natural History of Hepatitis B: Extra-hepatic Manifestations and Quality of Life. The Goal of Treatment in Chronic Hepatitis B. Efficacy of Interferon and Pegylated Interferon. Efficacy of Lamivudine. Efficacy of Adefovir. Comparison Between Lamivudine, Interferon and Adefovir, and Combinations. Safety of Lamivudine. Safety of Adefovir. New Drugs in Development. First Line Treatment of Chronic Hepatitis B: Adefovir, Lamivudine or Interferon? Who Need to be Treated and How to Explain the Goals to the Patient? Management of Relapsers and Non Responders. Management of Patients Co-infected by HBV and HIV. Management of Transplanted Patients Infected by HBV. Cost-effectiveness of Treatment. Section 3: Biochemical Markers, an Alternative to Liver Biopsies. Advantage and Limits of Liver Biopsy. Advantage and Limits of Biochemical Markers.

O autorze

Poynard, Thierry